ACAD (ACADIA Corp) Forward P/S Multiple
Daybue sales and a stable neurological portfolio generate strong cash flow, which drives the dynamics of the ACADIA Pharmaceuticals (ACAD) forward P/S chart. The value 5.30 indicates the status of the current valuation. Absolute pricing power in the rare pathology market guarantees stability, while the development of Parkinson's disease treatments minimizes risks, providing resources for new scientific research.
Summary analytical data breakdowns for ACADIA Corp (ACAD)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ACADIA Pharmaceuticals|ACAD - Company Aggregate Debts|Debts to Book Capitalization ACADIA Corp|ACAD - Company Long-Term Liabilities|Company Short-Term Debts ACADIA Pharmaceuticals|Quick Liquidity Indicator acadia-pharm.com
- financial results and valuation multiples details:
ACAD - Net Profit|Future Profit ACADIA Pharmaceuticals|ACAD - Market Price to Net Income Ratio|Forward P/E Multiple ACADIA Pharmaceuticals Inc|ACAD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple ACADIA Corp|ACAD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months acadia-pharm.com|ACAD - Earnings per share growth in current year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:ACADIA Pharmaceuticals Inc. ACAD
To decouple the fundamental value of ACADIA Pharmaceuticals (ACAD) from market speculation, it is critical to evaluate the expected price-to-sales ratio, which compares current market capitalization with projected sales volumes. The stability of this metric is supported by the absence of production downtime due to the contract model and hub automation, which minimizes the risk of multiple inflation and confirms the business's resilience to operational shocks.
Competitors of ACADIA Pharmaceuticals (ACAD)
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX (Neurocrine) - Future Price to Revenue|Regencell - Forward P/S Multiple|Forward Price to Sales AXSM (Axsome Corp)|XENE: Forward P/S Multiple|vikingtherapeutics.com (VKTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Supernus|CPRX: Forward Price to Sales|Price-to-Projected Revenue Ratio Denali Therapeutics Inc (DNLI)|Forward Price-to-Revenue Multiple Harmony Corp HRMY|Forward P/S Multiple BHVN (Biohaven Ltd.)|Forward P/S Multiple amylyx.com AMLX|Trevi Therapeutics, Inc. - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Forward Price-to-Revenue Multiple|AVXL: Forward P/S Multiple|Market Cap to Future Revenue Ratio CeriBell EEG (CBLL)|Forward Price-to-Revenue Multiple PRTA|Forward P/S Multiple Alector Therapeutics|Forward Price-to-Revenue Multiple ANNX (Annexon)|Price to Expected Revenue Ratio OMER|Forward P/S Multiple NGNE (Neurogene Corp)|Market Cap to Expected Sales Ratio AC Immune Inc (ACIU)|Voyager Therapeutics - Forward P/S Multiple|neumoratx.com (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alpha Cognition Inc|Price-to-Projected Revenue Ratio CGTX|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|Market Cap to Expected Sales Ratio cassavasciences.com|Forward P/S Multiple ASRT (Assertio)|Forward P/S Multiple Coya Therapeutics Inc COYA|VistaGen Therapeutics Inc - Forward P/S Multiple|Ovid Therapeutics Inc. (OVID) - Forward Price-to-Revenue Multiple|ABOS: Forward P/S Multiple|cervomed.com (CRVO) - Forward P/S Multiple|ATHE (Alterity Therapeutics Ltd.) - Forward P/S Multiple|Market Cap to Projected Revenue CLNN (Clene Nanomedicine)|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|GRCE: Forward Price-to-Revenue Multiple|AIFF - Forward P/S Multiple|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|NeuroSense Therapeutics Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Forward P/S Multiple NRXS|Forward P/S Multiple heliusmedical.com (HSDT)|Forward P/S Multiple PASG (Passage Bio)|NEUP - Forward Price-to-Revenue Multiple|Minerva Neurosciences - Forward P/S Multiple|ATHA - Forward P/S Multiple|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Protagenic (PTIX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|Future Price to Revenue CHRO|ELYM: Forward P/S Multiple|Intra-Cellular Therapies, Inc. - Forward Price to Sales|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Forward P/S Multiple Marinus Pharmaceuticals Inc|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX - Forward Price-to-Revenue Multiple|Trevena - Forward P/S Multiple|VIGL - Forward P/S Multiple|WENA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cerevel Corp
